BrouwerACarhart-HarrisRL (2021) Pivotal mental states. J Psychopharmacol35: 319–352.
2.
ButlerMSeynaeveMNicholsonTR, et al. (2020) Psychedelic treatment of functional neurological disorder: a systematic review. Ther Adv Psychopharmacol10: 2045125320912125.
3.
DavisAKBarrettFSSoS, et al. (2021) Development of the psychological insight questionnaire among a sample of people who have consumed psilocybin or LSD. J Psychopharmacol35: 437–446.
4.
Dos SantosRHallakJBakerG, et al. (2021) Hallucinogen/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: evidence and mechanisms of action. J Psychopharmacol35: 453–458.
5.
Garcia-RomeuABarrettFSCarbonaroTM, et al. (2021) Optimal dosing for psilocybin pharmacotherapy: considering weight-adjusted and fixed dosing approaches. J Psychopharmacol35: 353–361.
6.
HirschfeldTSchmidtT (2021) Dose–response relationships of psilocybin-induced subjective experiences in humans. J Psychopharmacol35: 384–397.
7.
InserraADe GregorioD, et al. (2021) Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: an in vivo electrophysiology study in male mice. J Psychopharmacol35: 469–482.
8.
JefsenOHElfvingBWegenerG, et al. (2021) Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. J Psychopharmacol35: 483–493.
9.
MajicTSauterMBermpohlF, et al. (2021) Connected to the spirit of the frog. An Internet-based survey on Kambô, the secretion of the Amazonian Giant Maki Frog (Phyllomedusa bicolor): motivations for use, settings and subjective experiences. J Psychopharmacol35: 421–436.
10.
NuttDJKingLANicholsDE (2013) Effects of schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci14: 577–585.
11.
PallaviciniCCavannaFZamberlanF, et al. (2021) Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings. J Psychopharmacol35: 406–420.
12.
RamaekersJGHuttenNMasonNL, et al. (2021) A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. J Psychopharmacol35: 398–405.
13.
RuckerJJH (2015) Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential. BMJ350: h2902.
14.
RuckerJJHIliffJNuttDJ (2018) Psychiatry and the psychedelic drugs. Past, present and future. Neuropharmacology142: 200–218.
15.
RuckerJJHJelenLAFlynnS, et al. (2016) Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol30: 1220–1229.
16.
SchmidYGasserPOehenP, et al (2021) Acute subjective effects in LSD- and MDMA-assisted psychotherapy. J Psychopharmacol35: 362–374.
17.
SessaBHigbedLO’BrienS, et al. (2021) First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psycho-therapy in patients with alcohol use disorder. J Psychopharmacol35: 375–383.
18.
SimonssonOSextonJDHendricksPS (2021) Associations between lifetime classic psychedelic use and markers of physical health. J Psychopharmacol35: 447–452.
19.
StenbaekDSMadsenMKOzenneB, et al. (2021) Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. J Psychopharmacol35: 459–468.
20.
WestonNMGibbsDBirdCIV, et al. (2020) Historic psychedelic drug trials and the treatment of anxiety disorders. Depress Anxiety37: 1261–1279.
